Revvity
Revvity, formerly known as PerkinElmer Informatics, is a leading provider of innovative software solutions headquartered in the United States. Established in 2022, the company has quickly positioned itself at the forefront of the life sciences and healthcare industries, focusing on data analytics, laboratory informatics, and scientific data management. With a commitment to enhancing research and development processes, Revvity offers a suite of core products that streamline workflows and improve data accessibility. Their unique approach combines advanced analytics with user-friendly interfaces, enabling organisations to make informed decisions swiftly. Recognised for its significant contributions to the field, Revvity continues to expand its operational reach, serving clients across North America and beyond. The company’s dedication to innovation and excellence has solidified its reputation as a trusted partner in the scientific community.
DitchCarbon Score
How does Revvity's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revvity's score of 38 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Revvity's reported carbon emissions
In 2023, Revvity reported total greenhouse gas emissions of approximately 29,810,000 kg CO2e (market-based) and 31,702,000 kg CO2e (location-based) across Scope 1 and Scope 2. Specifically, Scope 1 emissions were about 2,121,000 kg CO2e, while Scope 2 emissions accounted for approximately 27,689,000 kg CO2e (market-based). This data reflects a slight decrease in Scope 1 emissions from 2,289,000 kg CO2e in 2022, while Scope 2 emissions also saw a reduction from 29,844,000 kg CO2e (market-based) in the previous year. Revvity has set ambitious climate commitments, aiming for a 50% reduction in Scope 1 and Scope 2 emissions by 2033, with the target established in 2022. Additionally, the company is committed to achieving net carbon neutrality by 2040, as outlined in their inaugural ESG report released in 2023. The emissions data and reduction targets are not cascaded from any parent organization, indicating that Revvity is independently managing its climate impact. The company operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector in the United States, and its ongoing initiatives reflect a proactive approach to addressing climate change and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,289,000 | 0,000,000 |
| Scope 2 | 29,844,000 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revvity is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
